Integrative Biomedical Research
Integrative Biomedical Research (Journal of Angiotherapy) | Online ISSN 3068-6326
463
Citations
1.9m
Views
782
Articles
Volume 10 Number 2 2026
REVIEWS (Open Access)
CRISPR Gene Editing Could Cure Duchenne Muscular Dystrophy but Fatal AAV Immune Responses Remain Unresolved
Muhammad Rizki Saputra 1*, Nor Hazliana Harun 2, Siti Salmah Noordin 3, Nabil Deb Nath 4, Md Abdur Rahman Biswash 5
Integrative Biomedical Research 10 (2) 1-8 https://doi.org/10.25163/biomedical.10210948
Submitted: 14 June 2026 Revised: 01 August 2026 Accepted: 10 August 2026 Published: 12 August 2026
Abstract
Duchenne muscular dystrophy (DMD) remains, despite decades of careful clinical management, a relentless disease - and for a long time, medicine could only slow it down, not stop it. That may be changing. CRISPR-Cas genome editing now offers something earlier therapies could not: a route to permanent, DNA-level correction of the mutations that silence dystrophin. This review draws together the molecular, delivery, and safety literature on CRISPR strategies for DMD, tracing how single-cut and double-cut non-homologous end joining, homology-independent targeted integration, base and prime editing, and CRISPR activation of utrophin each attempt to restore or compensate for lost dystrophin, depending on where and how a patient's mutation falls. It then turns to the harder, less glamorous problem: getting these tools into more than forty percent of the human body safely. Recombinant adeno-associated viruses remain the dominant in vivo vector, prized for their muscle tropism, yet constrained by a packaging ceiling near 4.7 kilobases and by immune responses that have, in several trials, proven fatal at the doses required for systemic correction. High-capacity adenoviral vectors and non-viral platforms - lipid nanoparticles, extracellular vesicles, and gold nanoparticles - are examined as partial answers, each trading some efficiency for a better safety margin. Evidence from mouse, canine, porcine, and human iPSC-derived models is synthesized to show where preclinical promise has, and has not, translated toward the clinic. Taken together, the literature suggests that vector engineering, transient non-viral delivery, and precision DSB-free editors, paired with realistic manufacturing and immunosuppression strategies, will likely determine whether CRISPR therapeutics for DMD become a durable clinical reality rather than a preclinical curiosity.
Keywords: Duchenne muscular dystrophy; CRISPR-Cas genome editing; Dystrophin restoration; AAV gene delivery; Base and prime editing; non-viral delivery systems; Preclinical disease models
References
Ali, A., Rahman, M. Y., & Sheikh, D. (2024). The role of CRISPR/Cas9 in revolutionizing Duchenne's muscular dystrophy treatment: Opportunities and obstacles. Global Medical Genetics, 11(4), 349–357. https://doi.org/10.1055/s-0044-1791803
Amoasii, L., Hildyard, J. C. W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D., Harron, R., Stathopoulou, T.-R., Massey, C., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2018). Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science, 362(6410), 86–91. https://doi.org/10.1126/science.aau1549
Amoasii, L., Long, C., Li, H., Mireault, A. A., Shelton, J. M., Sanchez-Ortiz, E., McAnally, J. R., Bhattacharyya, S., Schmidt, F., Grimm, D., Bassel-Duby, R., & Olson, E. N. (2017). Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Science Translational Medicine, 9(418), eaan8081. https://doi.org/10.1126/scitranslmed.aan8081
Andreana, I., Repellin, M., Kryza, D., Briancon, S., Arpicco, S., & Stella, B. (2021). Nanomedicine-based strategies for the treatment of muscular dystrophies. Pharmaceutics, 13(2), 278. https://doi.org/10.3390/pharmaceutics13020278
Andrysiak, K., Ferdek, P. E., Sanetra, A. M., Machaj, G., Schmidt, L., Kraszewska, I., Sarad, K., Palus-Chramiec, K., Lis, O., Targosz-Korecka, M., & Dulak, J. (2024). Upregulation of utrophin improves the phenotype of Duchenne muscular dystrophy hiPSC-derived CMs. Molecular Therapy: Nucleic Acids, 35(1), 102247. https://doi.org/10.1016/j.omtn.2024.102247
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., & Liu, D. R. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7786), 149–157. https://doi.org/10.1038/s41586-019-1711-4
Bonowicz, K., Jerka, D., Piekarska, K., Olagbaju, J., Stapleton, L., Shobowale, M., Bartosinski, A., Lapot, M., Bai, Y., & Gagat, M. (2025). CRISPR-Cas9 in cardiovascular medicine: Unlocking new potential for treatment. Cells, 14(2), 131. https://doi.org/10.3390/cells14020131
Brescia, M., Janssen, J. M., Liu, J., & Gonçalves, M. A. F. V. (2020). High-capacity adenoviral vectors permit robust and versatile testing of DMD gene repair tools and strategies in human cells. Cells, 9(4), 869. https://doi.org/10.3390/cells9040869
Chemello, F., Chai, A. C., Li, H., Rodriguez-Caycedo, C., Sanchez-Ortiz, E., Atmanli, A., Mireault, A. A., Liu, N., Bassel-Duby, R., & Olson, E. N. (2021). Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Science Advances, 7(18), eabg4910. https://doi.org/10.1126/sciadv.abg4910
Chen, G., Wei, T., Yang, H., Li, G., & Li, H. (2022). CRISPR-based therapeutic gene editing for Duchenne muscular dystrophy: Advances, challenges and perspectives. Cells, 11(19), 2964. https://doi.org/10.3390/cells11192964
Choi, E., & Koo, T. (2021). CRISPR technologies for the treatment of Duchenne muscular dystrophy. Molecular Therapy, 29(12), 3179–3191. https://doi.org/10.1016/j.ymthe.2021.04.002
Egorova, T. V., Zotova, E. D., Reshetov, D. A., Polikarpova, A. V., Vassilieva, S. G., Vlodavets, D. V., Gavrilov, A. A., Ulianov, S. V., Buchman, V. L., & Deykin, A. V. (2019). CRISPR/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene. Disease Models & Mechanisms, 12(4), dmm037655. https://doi.org/10.1242/dmm.037655
El Andari, J., Renaud-Gabardos, E., Tulalamba, W., Weinmann, J., Mangin, L., Pham, Q. H., Hille, S., Bennett, A., Attebi, E., Bourges, E., & Grimm, D. (2022). Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders. Science Advances, 8(36), eabn4704. https://doi.org/10.1126/sciadv.abn4704
Erkut, E., & Yokota, T. (2022). CRISPR therapeutics for Duchenne muscular dystrophy. International Journal of Molecular Sciences, 23(3), 1832. https://doi.org/10.3390/ijms23031832
Farzi, F., Soltanmohammadi, F., Mohammadi, S. A., Zarghami, N., & Alizadeh, E. (2026). Transforming Duchenne muscular dystrophy therapy: The multifaceted role of extracellular vesicles and exosomes. Biochemistry and Biophysics Reports, 46, 102578. https://doi.org/10.1016/j.bbrep.2026.102578
Happi Mbakam, C., Lamothe, G., Tremblay, G., & Tremblay, J. P. (2022). CRISPR-Cas9 gene therapy for Duchenne muscular dystrophy. Neurotherapeutics, 19(3), 931–941. https://doi.org/10.1007/s13311-022-01197-9
Kenjo, E., Hozumi, H., Makita, Y., Iwabuchi, K. A., Fujimoto, N., Matsumoto, S., Kimura, M., Amano, Y., Ifuku, M., Naoe, Y., & Hotta, A. (2021). Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nature Communications, 12(1), 7101. https://doi.org/10.1038/s41467-021-26714-w
Koo, T., Lu-Nguyen, N. B., Malerba, A., Kim, E., Kim, D., Cappellari, O., Cho, H. Y., Dickson, G., Popplewell, L., & Kim, J. S. (2018). Functional rescue of dystrophin deficiency in mice caused by frameshift mutations using Campylobacter jejuni Cas9. Molecular Therapy, 26(6), 1529–1538. https://doi.org/10.1016/j.ymthe.2018.03.017
Kornegay, J. N., Bogan, J. R., Bogan, D. J., Childers, M. K., Li, J., Nghiem, P., Detwiler, D. A., Larsen, C. A., Grange, R. W., Bhavaraju-Sanka, R. K., & Xiao, X. (2012). Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mammalian Genome, 23(1–2), 85–108. https://doi.org/10.1007/s00335-011-9382-y
Krishna, L., Prashant, A., Kumar, Y. H., Paneyala, S., Patil, S. J., Ramachandra, S. C., & Vishwanath, P. (2024). Molecular and biochemical therapeutic strategies for Duchenne muscular dystrophy. Neurology International, 16(4), 731–760. https://doi.org/10.3390/neurolint16040055
Kuroda, T., & Yokota, T. (2026). RNA therapeutics targeting skeletal muscle: Emerging antisense and gene-modifying strategies. Biomolecules, 16(5), 794. https://doi.org/10.3390/biom16050794
Laurent, M., Geoffroy, M., Pavani, G., & Guiraud, S. (2024). CRISPR-based gene therapies: From preclinical to clinical treatments. Cells, 13(10), 800. https://doi.org/10.3390/cells13100800
Leal, A. F., Herreno-Pachón, A. M., Benincore-Flórez, E., Karunathilaka, A., & Tomatsu, S. (2024). Current strategies for increasing knock-in efficiency in CRISPR/Cas9-based approaches. International Journal of Molecular Sciences, 25(4), 2456. https://doi.org/10.3390/ijms25042456
Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., & Conboy, I. M. (2017). Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nature Biomedical Engineering, 1(11), 889–901. https://doi.org/10.1038/s41551-017-0137-2
Liao, H. K., Hatanaka, F., Araoka, T., Reddy, P., Wu, M. Z., Sui, Y., Yamauchi, T., Sakurai, M., O’Keefe, D. D., Núñez-Delicado, E., & Belmonte, J. C. I. (2017). In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation. Cell, 171(7), 1495–1507. https://doi.org/10.1016/j.cell.2017.10.025
Lim, K. R. Q., Nguyen, Q., Dzierlega, K., Huang, Y., & Yokota, T. (2020). CRISPR-generated animal models of Duchenne muscular dystrophy. Genes, 11(3), 342. https://doi.org/10.3390/genes11030342
Lim, K. R. Q., Yoon, C., & Yokota, T. (2018). Applications of CRISPR/Cas9 for the treatment of Duchenne muscular dystrophy. Journal of Personalized Medicine, 8(4), 38. https://doi.org/10.3390/jpm8040038
Loboda, A., Chamberlain, J. S., & Dulak, J. (2025). Genetic strategies for therapy of Duchenne muscular dystrophy. Molecular Therapy: Nucleic Acids, 36, 102759. https://doi.org/10.1016/j.omtn.2025.102759
Lu, X., Zhang, M., Li, G., Zhang, S., Zhang, J., Fu, X., & Sun, F. (2023). Applications and research advances in the delivery of CRISPR/Cas9 systems for the treatment of inherited diseases. International Journal of Molecular Sciences, 24(17), 13202. https://doi.org/10.3390/ijms241713202
Min, Y. L., Li, H., Rodriguez-Caycedo, C., Mireault, A. A., Huang, J., Shelton, J. M., McAnally, J. R., Amoasii, L., Mammen, P. P. A., Bassel-Duby, R., & Olson, E. N. (2019). CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Science Advances, 5(3), eaav4324. https://doi.org/10.1126/sciadv.aav4324
Mollanoori, H., Rahmati, Y., Hassani, B., Havasi Mehr, M., & Teimourian, S. (2020). Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy. Genes & Diseases, 8(2), 146–156. https://doi.org/10.1016/j.gendis.2019.12.007
Montagna, C., Maiani, E., Pieroni, L., & Consalvi, S. (2025). Duchenne muscular dystrophy: Integrating current clinical practice with future therapeutic and diagnostic horizons. International Journal of Molecular Sciences, 26(14), 6742. https://doi.org/10.3390/ijms26146742
Nakamura, K., Fujii, W., Tsuboi, M., Tanihata, J., Teramoto, N., Takeuchi, S., Naito, K., Yamanouchi, K., & Nishihara, M. (2014). Generation of muscular dystrophy model rats with a CRISPR/Cas system. Scientific Reports, 4, 5635. https://doi.org/10.1038/srep05635
Pickar-Oliver, A., Gough, V., Bohning, J. D., Liu, S., Robinson-Hamm, J. N., Daniels, H., Majoros, W. H., Devlin, G., Asokan, A., & Gersbach, C. A. (2021). Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. Molecular Therapy, 29(11), 3243–3257. https://doi.org/10.1016/j.ymthe.2021.08.031
Saad, F. A., Siciliano, G., & Angelini, C. (2023). Advances in dystrophinopathy diagnosis and therapy. Biomolecules, 13(9), 1319. https://doi.org/10.3390/biom13091319
Siddika, A., Rousseau, J., Veillette, F., Bouchard, C., Lu, Y., & Tremblay, J. P. (2026). Gene editing strategies for Duchenne muscular dystrophy: From molecular mechanisms to clinical translation. Cells, 15(9), 852. https://doi.org/10.3390/cells15090852
Tabebordbar, M., Lagerborg, K. A., Stanton, A., King, E. M., Ye, S., Tellez, L., Krunnfusz, A., Tavakoli, S., Widrick, J. J., Messemer, K. A., & Wagers, A. J. (2021). Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell, 184(19), 4919–4938.e22. https://doi.org/10.1016/j.cell.2021.08.028
Weinmann, J., Weis, S., Sippel, J., Tulalamba, W., Remes, A., El Andari, J., Herrmann, A. K., Pham, Q. H., Borowski, C., Hille, S., & Grimm, D. (2020). Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nature Communications, 11(1), 5432. https://doi.org/10.1038/s41467-020-19230-w
Wojtal, D., Kemaladewi, D. U., Malam, Z., Abdullah, S., Wong, T. W., Hyatt, E., Baghestani, Z., McMillan, H. J., & Cohn, R. D. (2016). Spell-checking nature: Pathogenicity-driven precision genome editing in Duchenne muscular dystrophy. American Journal of Human Genetics, 98(1), 90–101. https://doi.org/10.1016/j.ajhg.2015.11.021
Young, C. S., Mokhonova, E., Quinonez, M., Pyle, A. D., & Spencer, M. J. (2017). Creation of a novel humanized dystrophic mouse model of Duchenne muscular dystrophy and application of a CRISPR/Cas9 gene editing therapy. Journal of Neuromuscular Diseases, 4(2), 139–145. https://doi.org/10.3233/JND-170218
Zhang, Y., Li, H., Nishiyama, T., McAnally, J. R., Sanchez-Ortiz, E., Huang, J., Mammen, P. P., Bassel-Duby, R., & Olson, E. N. (2022). A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing. Molecular Therapy: Nucleic Acids, 29, 525–537. https://doi.org/10.1016/j.omtn.2022.07.024
Zhang, Y., Nishiyama, T., Li, H., Huang, J., Atmanli, A., Sanchez-Ortiz, E., Wang, Z., Mireault, A. A., Mammen, P. P. A., Bassel-Duby, R., & Olson, E. N. (2021). A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation. Molecular Therapy - Methods & Clinical Development, 22, 122–132. https://doi.org/10.1016/j.omtm.2021.05.014
Zhao, X., Qu, K., Curci, B., Yang, H., Bolund, L., Lin, L., & Luo, Y. (2023). Comparison of in-frame deletion, homology-directed repair, and prime editing-based correction of Duchenne muscular dystrophy mutations. Biomolecules, 13(5), 870. https://doi.org/10.3390/biom13050870